Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib rollover access study for patients benefiting from prior Novartis LEE011 trials
2016-000293-37Phase 2Active
- Sponsor
- Novartis
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ribociclib in cancer (2 arms), sponsored by Novartis. Primary endpoints: Number of patients receiving ribociclib under rollover study and Duration of exposure. Started Sep 2016; status: active.
02
Drugs
ribociclib
03
Conditions
cancer
Beyond the preview
Go deeper on 2016-000293-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000293-37.